What is Seres Therapeutics, Inc. (MCRB) stock price today?

Seres Therapeutics, Inc. (MCRB) is currently trading at $2.71, up 3.04% today.

What is MCRB P/E ratio?

Seres Therapeutics, Inc.'s P/E ratio is -1.21. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is MCRB return on equity (ROE)?

Seres Therapeutics, Inc.'s return on equity (ROE) is -60.32%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Seres Therapeutics, Inc.'s market cap?

Seres Therapeutics, Inc. has a market capitalization of $26.24M.

NASDAQ · Biotechnology

Seres Therapeutics, Inc. (MCRB) Stock

$2.71 +3.04% NASDAQ: MCRB Healthcare

Valuation

Metric	Value
Price	$2.71
Market Cap	$26.24M
P/E Ratio	-1.21
P/B Ratio	0.82
P/S Ratio	15.12
EPS (TTM)	$0.64
52-Week High	$29.98
52-Week Low	$2.54
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-60.32%
ROA	-22.11%
ROCE	-103.04%
Gross Margin	-9400.00%
Operating Margin	-9400.00%
Net Margin	-40.89%
Debt/Equity	1.64
Current Ratio	2.58

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$145.0M	$0	$0	$0	$1.0M
Operating Profit	$-64.0M	$-180.0M	$-195.0M	$-121.0M	$-94.0M
Net Profit	$-66.0M	$-250.0M	$-114.0M	$-147.0M	$6.0M
EPS	$-14.30	$-46.29	$-17.77	$-18.86	$0.64
Op Margin	-44.5%	—	—	—	-11910.1%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$355.0M	$349.0M	$359.0M	$140.0M	$138.0M
Total Liabilities	$223.0M	$338.0M	$403.0M	$126.0M	$94.0M
Cash	$180.0M	$163.0M	$128.0M	$31.0M	$46.0M
Borrowings	$49.0M	$163.0M	$199.0M	$92.0M	$83.0M

Latest News

Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study MarketBeat · Jul 10, 2026 Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday MT Newswires · Jul 8, 2026 Seres Therapeutics' Phase 1 Trial of SER-155 Meets Primary Endpoint; Shares Rise Pre-Bell MT Newswires · Jul 8, 2026 Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment GlobeNewswire · Jul 8, 2026 Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis GlobeNewswire · Jun 25, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$7.0M	$-229.0M	$-117.0M	$-149.0M	$1.0M
Investing Cash Flow	$55.0M	$73.0M	$3.0M	$142.0M	$0
Financing Cash Flow	$0	$3.0M	$3.0M	$14.0M	$0
Net Cash Flow	$72.0M	$-17.0M	$-35.0M	$-97.0M	$15.0M
Free Cash Flow	$-3.0M	$-239.0M	$-125.0M	$-149.0M	$1.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-1.57
FCF Yield	-180.17%
Quick Ratio	2.11
Interest Coverage	0.00
Return 1Y	-62.92%
Return 3Y	-93.98%
Return 5Y	-98.69%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$336.64	-1.11%	38.93	$4.94T	0.32%
MSFTMicrosoft Corporation	$535.07	+2.38%	28.68	$3.97T	0.76%
GOOGLAlphabet Inc.	$351.66	+0.97%	16.94	$4.26T	0.26%
AMZNAmazon.com, Inc.	$262.43	+3.29%	19.82	$2.82T	0.00%
METAMeta Platforms, Inc.	$718.67	-0.31%	27.93	$1.83T	0.28%

About Seres Therapeutics, Inc.

Seres Therapeutics, Inc. is led by CEO Richard N. Kender, employs 103 people, headquartered in US, publicly traded since 2015.

Seres Therapeutics, Inc. (MCRB) stock trades at $2.71 with a market capitalization of $26.24M. The stock is valued at a price-to-earnings (P/E) ratio of -1.21, price-to-book of 0.82, price-to-sales of 15.12. Over the past 52 weeks the stock has ranged between $2.54 and $29.98, and currently trades 91.0% below its 52-week high.

On profitability, Seres Therapeutics, Inc. generates a return on equity (ROE) of -60.32%, return on capital employed of -103.04%, an operating margin of -9400.00%, a net profit margin of -40.89%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides